Emergent BioSolutions (NYSE:EBS) Stock Price Up 11.9% - What's Next?

Shares of Emergent BioSolutions Inc. (NYSE:EBS - Get Free Report) rose 11.9% during trading on Monday . The company traded as high as $9.26 and last traded at $9.25. Approximately 357,293 shares were traded during trading, a decline of 88% from the average daily volume of 3,102,595 shares. The stock had previously closed at $8.27.

Analysts Set New Price Targets

EBS has been the topic of a number of research analyst reports. HC Wainwright started coverage on Emergent BioSolutions in a report on Monday. They issued a "buy" rating and a $15.00 target price on the stock. Rodman & Renshaw reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research note on Friday, September 13th. StockNews.com downgraded shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Benchmark lifted their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a report on Thursday, November 7th.

Emergent BioSolutions Stock Up 11.9 %

The stock has a market capitalization of $501.20 million, a price-to-earnings ratio of -2.26 and a beta of 1.59. The firm has a 50-day moving average of $9.19 and a 200 day moving average of $8.91. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Institutional Investors Weigh In On Emergent BioSolutions

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EBS. SeaCrest Wealth Management LLC grew its stake in shares of Emergent BioSolutions by 3.2% during the third quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company's stock valued at $991,000 after acquiring an additional 3,705 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Emergent BioSolutions during the 2nd quarter valued at approximately $41,000. Verus Capital Partners LLC purchased a new stake in Emergent BioSolutions during the 2nd quarter worth approximately $68,000. Stifel Financial Corp acquired a new position in shares of Emergent BioSolutions in the 3rd quarter valued at approximately $96,000. Finally, FORA Capital LLC purchased a new position in shares of Emergent BioSolutions during the 3rd quarter valued at approximately $103,000. Hedge funds and other institutional investors own 78.40% of the company's stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.